Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
The product of SSX2 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. Zusätzlich bieten wir Ihnen Synovial Sarcoma, X Breakpoint 2 Proteine (6) und Synovial Sarcoma, X Breakpoint 2 Kits (1) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 64 products:
Human Monoclonal SSX2 Primary Antibody für IHC (p), ELISA - ABIN520520
Smith, Cronk, Lang, McNeel: Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. in Cancer research 2011
Show all 2 Pubmed References
Human Polyclonal SSX2 Primary Antibody für WB - ABIN2780224
Fernebro, Francis, Edén, Borg, Panagopoulos, Mertens, Vallon-Christersson, Akerman, Rydholm, Bauer, Mandahl, Nilbert: Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma. in International journal of cancer. Journal international du cancer 2005
Show all 2 Pubmed References
We conclude from these findings that SSX2 expression in prostate cancer is not a driver of the epithelial to mesenchymal transition (EMT (zeige ITK Antikörper)), but is involved in processes associated with EMT (zeige ITK Antikörper) including loss of focal adhesion that may be related to tumor cell dissemination
Meta-analysis of human synovial sarcoma patient series identified two tumor-gentoype-phenotype correlations that were not modeled by the mice, namely a scarcity of male hosts and biphasic histologic features among SS18 (zeige SS18 Antikörper)-SSX2 tumors. Re-analysis of human SS18 (zeige SS18 Antikörper)-SSX1 (zeige SSX1 Antikörper) and SS18 (zeige SS18 Antikörper)-SSX2 tumor transcriptomes demonstrated very few consistent differences, but highlighted increased native SSX2 expression in SS18 (zeige SS18 Antikörper)-SSX1 (zeige SSX1 Antikörper) tumors.
results reveal two important phenotypes of ectopic SSX2 expression that may drive/support tumorigenesis: First, immediate induction of genomic instability, and second, long-term support of tumor cell growth.
The tumor-specific pattern of expression of SSX2.
primary autoantibodies against intracellular MM-specific tumor antigens SSX-2 and NY-ESO-1 (zeige CTAG1B Antikörper) are rare but functional in multiple myeloma patients after allogeneic stem cell transplantation
SS18 (zeige SS18 Antikörper)-SSX-induced Wnt (zeige WNT2 Antikörper)/beta-catenin (zeige CTNNB1 Antikörper) signaling appears to be of crucial biological importance in synovial sarcoma tumorigenesis and progression.
SSX2, SSX3 (zeige SSX3 Antikörper), and SSX4 (zeige SSX4 Antikörper) are expressed in the lung tissue of only 3.5% early-stage non-small cell lung cancer patients.
These results suggest that the characteristic speckle localization pattern of SS18 (zeige SS18 Antikörper)-SSX is strongly involved in the tumorigenesis through the SSX moiety of the SS18 (zeige SS18 Antikörper)-SSX fusion protein.
the initial events that likely occur when SYT (zeige SS18 Antikörper)-SSX2 is first expressed, and its dominant function in subverting the nuclear program of the stem cell, leading to its aberrant differentiation, as a first step toward transformation
The regulation of estrogen receptor alpha (zeige ESR1 Antikörper) signaling by target proteins of SSX2 may explain the metastatic potential of breast cancer cells.
The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X\\\\;18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity. Two transcript variants encoding distinct isoforms have been identified for this gene.
cancer/testis antigen 5.2
, cancer/testis antigen family 5, member 2a
, protein SSX2
, sarcoma, synovial, X-chromosome-related 2
, synovial sarcoma, X breakpoint 2B
, tumor antigen HOM-MEL-40
, synovial sarcoma, X breakpoint 2
, synovial sarcoma, X breakpoint 3
, protein SSX1
, putative protein SSX10
, putative protein SSX6-like